RECRUITING

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a randomized, double-blind, placebo-controlled, phase 1b study designed to evaluate safety, tolerability, PK, and preliminary efficacy of APL-1401 in patients with moderately to severely active UC. This study comprises 3 periods including screening period (D-28\~D-1), treatment period (D1-D28), and safety follow-up period(D29-D58).

Official Title

A Phase 1b Randomized, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Quick Facts

Study Start:2023-01-26

Study Completion:2025-04

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05743010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Willing and able to provide written informed consent. 2. Age 18-65 years (inclusive). 3. With a history of UC diagnosis at least 3 months prior to screening. 4. Currently has active UC, defined as a Total Mayo Score of 6 to 12 (inclusive), at baseline, and with a Mayo Endoscopic Sub-Score (MESS) ≥ 2 confirmed by a site reader. 5. Has a rectal bleeding score ≥1 and a stool frequency Score ≥1 and in addition to MESS ≥2 during screening. 6. May be receiving the following drugs: 1. Oral 5-ammosahcylate (5-ASA) class of medications (mesalamine, olsalazine, balsalazide, sulfasalazine), provided the prescribed dose has been stable for at least 4 weeks prior to randomization; dose must be stable during the treatment period. 2. Oral corticosteroid therapy (prednisone prescribed at a stable dose ≤ 30 mg/day or budesonide prescribed at a stable dose of ≤ 9 mg/day), provided the prescribed dose has been stable for at least 2 weeks prior to randomization; during the treatment period, the same dose should be maintained but can be tapered by the investigators. 7. Women of childbearing potential must have a negative pregnancy test at screening visit and agree to use 2 highly effective methods of birth control at the same time during entire study period. 8. Male subjects must agree to use protocol specified method(s) of contraception from screening visit until 3 months after last dose.	1. Has fulminant colitis, toxic megacolon, primary sclerosing cholangitis, Crohn's disease, history of colitis-associated colonic dysplasia, active peptic ulcer disease. 2. Has a current clinically significant bacterial, parasitic, fungal, or viral infection. 3. Is positive for hepatitis A, B or C, human immunodeficiency virus (HIV), or tuberculosis. 4. Uses any of the following medications: 1. Intravenous corticosteroids 1 week prior to randomization; 2. Topical 5-ASA compounds or topical steroid (i.e., enemas or suppositories) 2 weeks prior to randomization; 3. Anti-diarrheal medications 2 weeks prior to randomization; 4. Sphingosine 1-phosphate receptor (S1PR) modulator including ozanimod 9 prior to randomization; 5. JAK inhibitors including tofacitinib and upadacitinib 4 weeks prior to randomization; 6. TNF-α antagonist including (but not limited to) infliximab, adalimumab, golimumab, certolizumab, or biosimilar agents 10 weeks prior to randomization; 7. Integrin antagonist, including vedolizumab 18 weeks prior to screening and natalizumab 10 weeks prior to screening; 8. Interleukin antagonist including ustekinumab 14 weeks prior to screening; 9. Patients receiving any of the following medications, if they were not discontinued at least 2 weeks prior to randomization: azathioprine, 6-mercaptopurine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, thalidomide. See Table 1; 10. Prohibited concomitant medications as described in Section 6.5.2 Table 1. 5. Participated in another clinical study of an investigational drug (or medical device) within 30 days prior to screening or is currently participating in another study of an investigational drug (or medical device). 6. Has clinically significant abnormalities in laboratory tests (complete blood count, chemistry panel, TSH, total T3, free T4, urinalysis 1. Hepatic panel (AST, ALT, total bilirubin) \>2 times the upper limits of normal (ULN) 2. Estimated CrCl \<60 mL/min as calculated by the Cockcroft-Gault equation 3. Thyroid stimulating hormone (TSH) \<2.5 mIU/L or \>4.2 mIU/L 7. Has a resting heart rate (HR) of \<50 bpm or \>120 bpm. 8. Has a resting systolic blood pressure \>160 mmHg or \<90 mmHg. 9. With thyroid disease or history thyroid surgery or on thyroid medications 10. Has orthostatic hypotension (decrease in systolic blood pressure \>20 mmHg or decrease in diastolic blood pressure \>10 mmHg when going from supine to standing) or a history of clinically significant orthostatic dizziness. 11. Treatment with Class Ia or Class III anti-arrhythmic drugs or treatment with two or more agents in combination known to prolong PR interval. 12. Is taking concomitant beta-blockers (including ophthalmologic timolol), amiodarone, reserpine, clonidine, monoamine oxidase (MAO) inhibitors, alpha blocking drugs, vasodilators which could enhance the production of catecholamines (hydralazine and nitrates), substrates or inhibitors of N-acetyltransferase. 13. Alcohol abuse or alcohol dependence at least 3 months prior to first dose. 14. With history of drug-related rash or has clinically significant rash or pruritus. 15. Has severe COVID-19 infection and needs to use ventilator or other treatments that make using of study drug impossible. 16. With moderate to severe (Child-Pugh Class B and Class C) hepatic impairment.

Inclusion Criteria

Exclusion Criteria

1. Willing and able to provide written informed consent.
2. Age 18-65 years (inclusive).
3. With a history of UC diagnosis at least 3 months prior to screening.
4. Currently has active UC, defined as a Total Mayo Score of 6 to 12 (inclusive), at baseline, and with a Mayo Endoscopic Sub-Score (MESS) ≥ 2 confirmed by a site reader.
5. Has a rectal bleeding score ≥1 and a stool frequency Score ≥1 and in addition to MESS ≥2 during screening.
6. May be receiving the following drugs:
1. Oral 5-ammosahcylate (5-ASA) class of medications (mesalamine, olsalazine, balsalazide, sulfasalazine), provided the prescribed dose has been stable for at least 4 weeks prior to randomization; dose must be stable during the treatment period.
2. Oral corticosteroid therapy (prednisone prescribed at a stable dose ≤ 30 mg/day or budesonide prescribed at a stable dose of ≤ 9 mg/day), provided the prescribed dose has been stable for at least 2 weeks prior to randomization; during the treatment period, the same dose should be maintained but can be tapered by the investigators.
7. Women of childbearing potential must have a negative pregnancy test at screening visit and agree to use 2 highly effective methods of birth control at the same time during entire study period.
8. Male subjects must agree to use protocol specified method(s) of contraception from screening visit until 3 months after last dose.

1. Has fulminant colitis, toxic megacolon, primary sclerosing cholangitis, Crohn's disease, history of colitis-associated colonic dysplasia, active peptic ulcer disease.
2. Has a current clinically significant bacterial, parasitic, fungal, or viral infection.
3. Is positive for hepatitis A, B or C, human immunodeficiency virus (HIV), or tuberculosis.
4. Uses any of the following medications:
1. Intravenous corticosteroids 1 week prior to randomization;
2. Topical 5-ASA compounds or topical steroid (i.e., enemas or suppositories) 2 weeks prior to randomization;
3. Anti-diarrheal medications 2 weeks prior to randomization;
4. Sphingosine 1-phosphate receptor (S1PR) modulator including ozanimod 9 prior to randomization;
5. JAK inhibitors including tofacitinib and upadacitinib 4 weeks prior to randomization;
6. TNF-α antagonist including (but not limited to) infliximab, adalimumab, golimumab, certolizumab, or biosimilar agents 10 weeks prior to randomization;
7. Integrin antagonist, including vedolizumab 18 weeks prior to screening and natalizumab 10 weeks prior to screening;
8. Interleukin antagonist including ustekinumab 14 weeks prior to screening;
9. Patients receiving any of the following medications, if they were not discontinued at least 2 weeks prior to randomization: azathioprine, 6-mercaptopurine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, thalidomide. See Table 1;
10. Prohibited concomitant medications as described in Section 6.5.2 Table 1.
5. Participated in another clinical study of an investigational drug (or medical device) within 30 days prior to screening or is currently participating in another study of an investigational drug (or medical device).
6. Has clinically significant abnormalities in laboratory tests (complete blood count, chemistry panel, TSH, total T3, free T4, urinalysis
1. Hepatic panel (AST, ALT, total bilirubin) \>2 times the upper limits of normal (ULN)
2. Estimated CrCl \<60 mL/min as calculated by the Cockcroft-Gault equation
3. Thyroid stimulating hormone (TSH) \<2.5 mIU/L or \>4.2 mIU/L
7. Has a resting heart rate (HR) of \<50 bpm or \>120 bpm.
8. Has a resting systolic blood pressure \>160 mmHg or \<90 mmHg.
9. With thyroid disease or history thyroid surgery or on thyroid medications
10. Has orthostatic hypotension (decrease in systolic blood pressure \>20 mmHg or decrease in diastolic blood pressure \>10 mmHg when going from supine to standing) or a history of clinically significant orthostatic dizziness.
11. Treatment with Class Ia or Class III anti-arrhythmic drugs or treatment with two or more agents in combination known to prolong PR interval.
12. Is taking concomitant beta-blockers (including ophthalmologic timolol), amiodarone, reserpine, clonidine, monoamine oxidase (MAO) inhibitors, alpha blocking drugs, vasodilators which could enhance the production of catecholamines (hydralazine and nitrates), substrates or inhibitors of N-acetyltransferase.
13. Alcohol abuse or alcohol dependence at least 3 months prior to first dose.
14. With history of drug-related rash or has clinically significant rash or pruritus.
15. Has severe COVID-19 infection and needs to use ventilator or other treatments that make using of study drug impossible.
16. With moderate to severe (Child-Pugh Class B and Class C) hepatic impairment.

Contacts and Locations

Study Contact

Qiuyue QU

CONTACT

+86 021 68583863

qyqu@asieris.cn

Principal Investigator

Qiuyue QU

STUDY_DIRECTOR

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Study Locations (Sites)

New Hope Research Development

Corona, California, 92882

United States

Guardian Angel Research Center

Tampa, Florida, 33614

United States

Tandem Clinical Research

Marrero, Louisiana, 70072

United States

Meridian Clinical Research

Rockville, Maryland, 20854

United States

Collaborators and Investigators

Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris

Qiuyue QU, STUDY_DIRECTOR, Jiangsu Yahong Meditech Co., Ltd aka Asieris

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-26

Study Completion Date2025-04

Study Record Updates

Study Start Date2023-01-26

Study Completion Date2025-04

Terms related to this study

Additional Relevant MeSH Terms

Ulcerative Colitis